WILL-EMI Study

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

WILL-EMI is a Phase 3 clinical study designed to investigate the efficacy and safety of emicizumab prophylaxis in male and female participants ≥1 month of age who have a diagnosis of Type 3 von Willebrand disease (VWD). Participants on prior standard of care (SOC) on-demand therapy will be randomized to receive emicizumab prophylaxis or to continue SOC on-demand therapy. Participants on prior SOC prophylactic therapy who were previously enrolled in the non-interventional (WILL-EMI-NIS) study will be switched to emicizumab prophylaxis in the WILL-EMI study and assessed via intra-participant analysis.

To learn more about the WILL-EMI study:

Visit the WILL-EMI Study Website
For participating sites and patient referrals, please click on the ClinicalTrials.gov link: WILL-EMI (NCT06998524)
Contact Genentech Trial Information Support: (888) 662-6728
(Monday - Friday, 5am - 5pm PT)